Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN’s Kidney Week 2021

FREMONT, Calif. and WALTHAM, Mass.: FREMONT, Calif. and WALTHAM, Mass., Nov. 5, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced multiple presentations covering additional positive...

Click to view original post